| Year |
Citation |
Score |
| 2017 |
Leeuwen Jv, Pandyra A, Goard C, Mullen PJ, Yu R, Penn LZ. Abstract 3543: Targeting the metabolic mevalonate pathway with statins as anti-breast cancer agents Cancer Research. 77: 3543-3543. DOI: 10.1158/1538-7445.Am2017-3543 |
0.685 |
|
| 2015 |
Pandyra AA, Mullen PJ, Goard CA, Ericson E, Sharma P, Kalkat M, Yu R, Pong JT, Brown KR, Hart T, Gebbia M, Lang KS, Giaever G, Nislow C, Moffat J, et al. Genome-wide RNAi analysis reveals that simultaneous inhibition of specific mevalonate pathway genes potentiates tumor cell death. Oncotarget. PMID 26353928 DOI: 10.18632/Oncotarget.4817 |
0.665 |
|
| 2015 |
Sriskanthadevan S, Jeyaraju DV, Chung TE, Prabha S, Xu W, Skrtic M, Jhas B, Hurren R, Gronda M, Wang X, Jitkova Y, Sukhai MA, Lin FH, Maclean N, Laister R, ... Goard CA, et al. AML cells have low spare reserve capacity in their respiratory chain that renders them susceptible to oxidative metabolic stress. Blood. 125: 2120-30. PMID 25631767 DOI: 10.1182/Blood-2014-08-594408 |
0.587 |
|
| 2014 |
Xu GW, Toth JI, da Silva SR, Paiva SL, Lukkarila JL, Hurren R, Maclean N, Sukhai MA, Bhattacharjee RN, Goard CA, Medeiros B, Gunning PT, Dhe-Paganon S, Petroski MD, Schimmer AD. Mutations in UBA3 confer resistance to the NEDD8-activating enzyme inhibitor MLN4924 in human leukemic cells. Plos One. 9: e93530. PMID 24691136 DOI: 10.1182/Blood.V122.21.2527.2527 |
0.339 |
|
| 2014 |
Goard CA, Chan-Seng-Yue M, Mullen PJ, Quiroga AD, Wasylishen AR, Clendening JW, Sendorek DH, Haider S, Lehner R, Boutros PC, Penn LZ. Identifying molecular features that distinguish fluvastatin-sensitive breast tumor cells. Breast Cancer Research and Treatment. 143: 301-12. PMID 24337703 DOI: 10.1007/S10549-013-2800-Y |
0.659 |
|
| 2014 |
Goard CA, Schimmer AD. Mitochondrial matrix proteases as novel therapeutic targets in malignancy Oncogene. 33: 2690-2699. PMID 23770858 DOI: 10.1038/Onc.2013.228 |
0.326 |
|
| 2013 |
Goard CA, Schimmer AD. An evidence-based review of obatoclax mesylate in the treatment of hematological malignancies. Core Evidence. 8: 15-26. PMID 23515850 DOI: 10.2147/Ce.S42568 |
0.432 |
|
| 2013 |
Wang Z, Dove P, Wang X, Goard CA, Li Z, Nachman A, Oh YJ, Hurren R, Ruschak A, Climie S, O'Neill D, Press B, Griffin C, Undzys E, Aman A, et al. FV-162 Is a Novel Orally Bioavailable Proteasome Inhibitor With Improved Pharmacokinetics That Displays Preclinical Efficacy In Vitro and In Vivo Blood. 122: 1988-1988. DOI: 10.1182/Blood.V122.21.1988.1988 |
0.359 |
|
| 2011 |
Mullen PJ, Goard CA, Wasylishen AR, Pandyra A, Penn LZ. Abstract C165: Breast cancer, statins, and 3-D cell culture. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-C165 |
0.662 |
|
| 2010 |
Goard CA, Mather RG, Vinepal B, Clendening JW, Martirosyan A, Boutros PC, Sharom FJ, Penn LZ. Differential interactions between statins and P-glycoprotein: implications for exploiting statins as anticancer agents. International Journal of Cancer. 127: 2936-48. PMID 21351272 DOI: 10.1002/Ijc.25295 |
0.559 |
|
| 2010 |
Martirosyan A, Clendening JW, Goard CA, Penn LZ. Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance. Bmc Cancer. 10: 103. PMID 20298590 DOI: 10.1186/1471-2407-10-103 |
0.643 |
|
| 2010 |
Goard C, Gauthier M, Penn L. 169 Identifying molecular hallmarks of sensitivity to the anticancer effects of statins in breast tumour cells European Journal of Cancer Supplements. 8: 58. DOI: 10.1016/S1359-6349(10)71874-7 |
0.431 |
|
| Show low-probability matches. |